New study results have demonstrated the potential of a new drug to reprogramme the immune profile in the tumour microenvironment (TME) and convert resistant tumours to responders to Immune Checkpoint Blockage (ICB) therapies. Purple Biotech shared the new results at the American Association for Cancer Research… Read More
Tisch Cancer Center scientists have developed unique models of acute myeloid leukaemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. The research was presented at the annual meeting of the American Association of Cancer Research and simultaneously… Read More
The latest sponsored DDW Sitting Down With podcast is now available for your listening pleasure. The podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer… Read More
The latest sponsored DDW Sitting Down With podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer Research Horizons is conducting at its site in Newcastle University; how Cancer Research… Read More
This article is sponsored by Taconic. The cancer therapeutic landscape changed dramatically with the introduction of immune checkpoint inhibitors (ICIs) that target T cells and leverage a patient’s immune system. Success in targeting T cells as immunotherapy has prompted investigators to explore whether other immune cell… Read More
Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Under a new strategic research collaboration, an ICR team led by Professor Chris Lord will investigate the effect of NeoPhore’s inhibitors on tumours in the laboratory. Read More
UK company Macomics presented data demonstrating its Enigmac macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting (AACR) in Florida. The company uses macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages are key players… Read More
The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study… Read More
DDW’s Megan Thomas rounds up highlights from Tuesday 17 April at AACR 2023, from AI and mathematical oncology to winners of the AACR James S Ewing-Thelma B Dunn Award for Outstanding Achievement in Pathology in Cancer Research. Clinical announcements Promising results for olaparib plus ceralasertib Today, results from the Phase… Read More
Exome sequencing correctly identified individuals with cancer predisposition syndromes who would have been missed by current screening guidelines, according to results from the Tapestry clinical trial. Data presented at the AACR Annual Meeting 2023 showed that among individuals who consented to whole-exome sequencing and were identified… Read More
A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data. The results from the Phase I portion of the Phase I/II… Read More
An investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant recurrence in patients with endometrial cancer, according to findings presented at the AACR Annual Meeting 2023. Endometrial cancer is the most common type of uterine cancer. While patients with early-stage uterine… Read More
Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. Read More
Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space. Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST… Read More
DDW’s Megan Thomas rounds up highlights from Monday 16 April at AACR 2023, from promising trial results for colorectal cancer patients to updates on Biden’s Cancer Moonshot initiative. Clinical announcements Data on colorectal cancer patients with African ancestry Today, data presented at the AACR Annual Meeting showed that genomic… Read More
Americans have become less aware that the human papillomavirus (HPV) causes cervical cancer in recent years, according to survey data presented at the AACR Annual Meeting 2023. Survey respondents also showed low awareness that HPV can cause anal, oral, and penile cancer. “Over 90%… Read More
